Patent ID: 9132190
Filing Date: 2015-09-15
Classification: A61K,A61P,C07K

Abstract:
1. A method for treating a subject having a disease or a disorder characterized by aberrant DLL4 expression or in which DLL4 is detrimental, said method comprising administering to said subject an effective amount of a binding protein capable of binding human DLL4, said binding protein comprising an antigen binding domain comprising six complementarity determining regions (CDRs): CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein: CDR-H1 is selected from the group consisting of: CDR-H2 is selected from the group consisting of: CDR-H3 is selected from the group consisting of: CDR-L1 is selected from the group consisting of: CDR-L2 is selected from the group consisting of: and CDR-L3 is selected from the group consisting of: